ANNX
Annexon·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANNX
Annexon, Inc.
A clinical-stage biopharmaceutical company that develops medicines for classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders
Biological Technology
03/03/2011
07/24/2020
NASDAQ Stock Exchange
100
12-31
Common stock
1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005
--
Annexon, Inc., was incorporated under the laws of the State of Delaware on March 3, 2011. The company is a clinical-stage biopharmaceutical company developing novel therapies for classical complement-mediated diseases of the body, brain and eyes.
Company Financials
EPS
ANNX has released its 2025 Q3 earnings. EPS was reported at -0.37, versus the expected -0.34, missing expectations. The chart below visualizes how ANNX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
